Interview
a16z Podcast | Players and Paths for Healthcare Startups
- Human healthcare technology development typically involves a complex, chronological sequence of discovery, regulatory approval, payment resolution, system education, and patient adoption that exceeds standard B2B or B2C models.
- Diagnostic startups may accelerate market entry and reduce risk by utilizing laboratory-derived tests (LDTs) through CLIA labs, offering a faster alternative to the lengthy therapeutic pathway.
- Therapeutic development entails a very long process requiring in vitro tests, animal studies, and traditional Phase One, Two, and Three clinical trials to secure regulatory permission for human use.
- Entrepreneurs may access a significant market opportunity by selling tools to the US R&D industry, a sector valued at $75 billion annually.
- Founders of transformative tools can generate recurring value through non-exclusive engagements with multiple industry players, avoiding the need to lock out competitors.
- Partnerships in platforms like monoclonal antibody design can secure an initial upfront payment alongside significant backend economics contingent on proven efficacy.
- Infrastructure providers such as Illumina can position themselves as essential by enabling the scale-up of cheap, reliable, and rapid full-genome sequencing, rendering previously impossible concepts viable.
- Go-to-market strategies must be tailored to the specific technology, such as utilizing the LDT path for broadly applicable diagnostics or adopting a partnership approach for platforms elucidating disease biology.
- Founders face a fundamental strategic choice between developing their own drugs or diagnostics or empowering the industry to create better drugs and diagnostics.
- Early company structuring and product definition require clear identification of required proofs of concept, regulatory approval pathways, and payment sources.
- Platforms aiming to broadly elucidate disease biology may find developing deep domain expertise across every disease in parallel difficult, suggesting that a partnership approach is often more viable.